- Home
- ALF vs TNGX Comparison
ALF vs TNGX Comparison
Compare ALF & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALF
- TNGX
- Stock Information
- Founded
- ALF 2024
- TNGX 2014
- Country
- ALF United States
- TNGX United States
- Employees
- ALF N/A
- TNGX N/A
- Industry
- ALF
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- ALF
- TNGX Health Care
- Exchange
- ALF NYSE
- TNGX Nasdaq
- Market Cap
- ALF 370.1M
- TNGX 317.4M
- IPO Year
- ALF 2024
- TNGX N/A
- Fundamental
- Price
- ALF $10.29
- TNGX $1.29
- Analyst Decision
- ALF
- TNGX Strong Buy
- Analyst Count
- ALF 0
- TNGX 7
- Target Price
- ALF N/A
- TNGX $12.33
- AVG Volume (30 Days)
- ALF 119.9K
- TNGX 756.3K
- Earning Date
- ALF 01-01-0001
- TNGX 05-07-2025
- Dividend Yield
- ALF N/A
- TNGX N/A
- EPS Growth
- ALF N/A
- TNGX N/A
- EPS
- ALF N/A
- TNGX N/A
- Revenue
- ALF N/A
- TNGX $42,069,000.00
- Revenue This Year
- ALF N/A
- TNGX N/A
- Revenue Next Year
- ALF N/A
- TNGX N/A
- P/E Ratio
- ALF $43.24
- TNGX N/A
- Revenue Growth
- ALF N/A
- TNGX 15.17
- 52 Week Low
- ALF $9.96
- TNGX $1.11
- 52 Week High
- ALF $10.30
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- ALF N/A
- TNGX 37.63
- Support Level
- ALF N/A
- TNGX $1.25
- Resistance Level
- ALF N/A
- TNGX $1.44
- Average True Range (ATR)
- ALF 0.00
- TNGX 0.15
- MACD
- ALF 0.00
- TNGX 0.03
- Stochastic Oscillator
- ALF 0.00
- TNGX 45.00
About ALF CENTURION ACQUISITION CORP
Centurion Acquisition Corp is a blank check company.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.